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Abstract
Background: Large HIV care programs frequently subsidize antiretroviral (ARV) drugs and CD4 tests, but patients must often
pay for other health-related drugs and services. We estimated the financial burden of health care for households with HIV-
infected adults taking antiretroviral therapy (ART) in Co ˆte d’Ivoire.
Methodology/Principal Findings: We conducted a cross-sectional survey. After obtaining informed consent, we
interviewed HIV-infected adults taking ART who had consecutively attended one of 18 HIV care facilities in Abidjan. We
collected information on socioeconomic and medical characteristics. The main economic indicators were household
capacity-to-pay (overall expenses minus food expenses), and health care expenditures. The primary outcome was the
percentage of households confronted with catastrophic health expenditures (health expenditures were defined as
catastrophic if they were greater than or equal to 40% of the capacity-to-pay). We recruited 1,190 adults. Median CD4 count
was 187/mm
3, median time on ART was 14 months, and 72% of subjects were women. Mean household capacity-to-pay was
$213.7/month, mean health expenditures were $24.3/month, and 12.3% of households faced catastrophic health
expenditures. Of the health expenditures, 75.3% were for the study subject (ARV drugs and CD4 tests, 24.6%; morbidity
events diagnosis and treatment, 50.1%; transportation to HIV care centres, 25.3%) and 24.7% were for other household
members. When we stratified by most recent CD4 count, morbidity events related expenses were significantly lower when
subjects had higher CD4 counts.
Conclusions/Significance: Many households in Co ˆte d’Ivoire face catastrophic health expenditures that are not attributable
to ARV drugs or routine follow-up tests. Innovative schemes should be developed to help HIV-infected patients on ART face
the cost of morbidity events.
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Introduction
The World Health Organization (WHO) estimated that 480,000
adults and children were living with HIV in Co ˆte d’Ivoire, West
Africa in late 2007. Of the 190,000 persons who were estimated to
be in need of antiretroviral therapy (ART), 51,812 (28%) were
actually receiving ART [1]. Most of these patients had started ART
withinthepreviousthree years,primarilythankstosupportfromthe
US President’s Emergency Plan for AIDS Relief (PEPFAR) and the
Global Fund to Fight AIDS, Tuberculosis and Malaria [2].
In most African countries that receive funds from these
international programs, antiretroviral drugs and follow-up tests
have become widely available at relatively low costs. In Co ˆte
d’Ivoire, HIV-infected patients paid a fixed rate of US$1.5 per
month per family from 2005 to 2008, to have access to ARV drugs
and CD4 count tests [3]. As of August 2008, ARV drugs and CD4
tests are entirely free for patients. All other health care expenses,
including cotrimoxazole prophylaxis, diagnostic tests, and treat-
ment of morbidity events after ART initiation, however, continue
to be borne by the patients [1,2]. The HIV virus reduces the
concentration of CD4+ T cells in the blood, thus suppressing the
immune system and increasing the risk of developing opportunistic
diseases. As CD4 counts decrease, the incidence of opportunistic
diseases increases. ART curbs viral replication in patients infected
with HIV, thereby restoring the immune system, increasing the
CD4+ T cell count, and reducing the risk of morbidity.
The financial burden of intercurrent morbidity events for HIV-
infected patients must be determined as a function of CD4 count,
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increases in CD4 counts [4–6]. Although it is reasonable to expect
that the financial burden of HIV on households decreases
considerably after ART initiation, preliminary evidence suggests
the contrary [2,4–6]. To explore this issue, the Co ˆte d’Ivoire
Ministry of Health has recommended that studies be conducted on
health care expenses among HIV-infected patients initiating ART
in Co ˆte d’Ivoire.
Here we report the health-related expenditures of adults on
ART in Co ˆte d’Ivoire.
Methods
Data collection
We conducted a two-month cross-sectional survey from June to
July 2007 in 18 health care facilities, 16 in Abidjan, the economic
capital, and two in provincial towns. These public or non-profit
private health centres all participate in the Aconda HIV care
network. Aconda, a non-governmental organization that is
dedicated to HIV/AIDS care and treatment, has been described
elsewhere [7]. Study participants were selected sequentially. One
patient out of every X patients who presented to care between
March 1 and April 30, 2007 was asked to participate. The
inclusion rate X differed by study center and was equal to
A/(B670%), where A was the sample size at the study center, B
was the anticipated number of patients who would visit the center
during the study period, and 70% was the anticipated proportion
of patients who would accept to participate. The sample size A at
each study center was the overall study sample size multiplied by
the number of patients in active follow-up at the study center and
divided by the number of patients in active follow-up at all 18
study centers.
Overall,1,451adultstakingARTwhohad attendedoneofthe 18
HIV care centres were randomly chosen to participate in a face-to-
face interview. 1,275 HIV-infected patients accepted to be
interviewed and gave verbal informed consent – informed consent
took the form of an open, easily understood communication process
between investigator and subject approved by the national ethics
committee. After obtaining verbal informed consent, investigators
used a standardized questionnaire to record data on household
structure, and expenses during the past three months.
When patients did not have some of the requested information,
we asked for their permission to contact the head of the household
or any other adult household member who could answer our
questions. The unit of observation was one patient per household.
Individual data on HIV disease, including most recent CD4
count and history of ART, were gathered from each patient’s
personal medical record at the HIV care centre.
This study was approved by the Ethics Committee of the Co ˆte
d’Ivoire Ministry of Health and the Institutional Review Board of
the French National Agency for AIDS research and viral hepatitis
(ANRS).
Variables definition
Total household expenditures were defined as the sum of the
expenses of all household members over the past three months.
Expenditures were classified as food expenditures, health care
expenditures, and other expenditures (electricity, water, telephone,
school fees, transportation non-related to health, etc) [8,9].
Household capacity-to-pay was defined as the household’s non-
subsistence expenses, i.e. total household expenditures minus food
expenditures [10–15].
Health expenditures were stratified into two groups: expendi-
tures related to treatment of the HIV-infected study subject, and
expenditures related to the treatment of other members of the
family (whose HIV serostatus was unknown). Health expenditures
for the HIV-infected study subjects were divided into three groups:
(i) ARV drugs and routine follow-up tests, which were available to
all HIV-infected patients living in Co ˆte d’Ivoire at a fixed rate of
US$ 1.5 per month at the time of the survey; (ii) other medical
expenditures (medical consultations, hospital stays, non-CD4 tests,
and non-ARV drugs), and (iii) non-medical health-related
expenditures (transportation to HIV care centres and housing
near health facilities).
Health expenditures are defined as catastrophic when they
exceed a given proportion of household resources [13,16]. We
used the WHO definition, which characterizes health expenses as
catastrophic when they are greater than or equal to 40% of a
household’s capacity-to-pay [11].
Statistical analysis
Expenses were estimated in US dollars ($). Each variable was
estimated per household. We determined the mean, standard
deviation, median, interquartile range, and range of the
distribution of each household characteristic in the study
population. Data were described both overall, and stratified by
most recent CD4 count (,100, 100–199, 200–349, 350–499, and
$500/mm
3). We analysed differences in main outcomes by CD4
category using parametric or non-parametric tests, depending on
the distribution of the variable. We determined the factors
associated with catastrophic health expenditures using univariate
and multivariate logistic regression.
Analyses were performed using STATA 10 software (StataCorp,
College Station, Texas, USA).
Results
Socio-demographic and clinical characteristics
Among the 1,275 HIV-infected patients on ART who accepted
to be interviewed and gave verbal informed consent, 85 (6.7%)
were excluded from the analysis, because their CD4 counts had
not been measured in the previous 12 months. Of the remaining
1,190 patients that we included in the analysis, 72% were female
and 45% were heads of household. The main clinical and socio-
demographic characteristics of these patients are reported in
Table 1. Nine percent of households had a health insurance
scheme.
Expenditures
Investigators collected information from 1,158 patients (97.3%)
on household structure and expenses in order to complete the
questionnaire. We interviewed other adult household members to
complete the questionnaire for the remaining 32 (2.7%) patients.
Mean overall household expenditures were $313.8 per house-
hold per month (Table 2). When we subtracted food from the
overall household expenditures, mean household capacity-to-pay
was $213.7 per month. Health care expenditures accounted on
average for 9.9% of overall household expenditures, and 17.7% of
the capacity-to-pay (standard deviation 0.5%, median 10.4%,
interquartile range [IQR] 5.2%–21.9%). On average, 75.3% of
health expenditures were for the study subjects (ARV drugs and
CD4 tests, 24.6%; other tests and drugs, 50.1%; and transporta-
tion to HIV care centre, 25.3%), and 24.7% were for other
members of the household.
Figure 1 and Figure 2 illustrate the components of household
health expenditures, stratified by most recent CD4 count. As
shown in Figure 1, overall health expenditures and expenditures
related to treatment of the study subject were significantly lower
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respectively). Health expenditures for other members of the
household did not differ significantly by CD4 count (p=0.77). As
shown in Figure 2, spending on ARV drugs and routine tests was
slightly lower, and spending on non-ARV drugs and non-CD4
tests was dramatically lower, when patients had higher CD4
counts. Both differences were significant (p,0.001 and p,0.001,
respectively).
Figure 3 shows the percentage of households whose health
expenditures/capacity-to-pay ratios reached various thresholds.
Twelve percent of households met the WHO definition for
catastrophic health care expenditures (health expenditures greater
than or equal to 40% of the household’s capacity-to-pay), 28% of
households had ratios above 20%, and 50% of households had
ratios above 10.4%.
The following factors were associated with catastrophic health
expenditures in multivariate analysis (Table 3): increased time spent
on ART (adjusted odds ratio [AOR] 0.97; 95% confidence interval
[CI] 0.94–0.99), female HIV-infected patients (AOR 0.58; 95%CI
0.46–1.33), secondary level of education of the household head
(AOR 0.31; 95%CI 0.15–0.63), increased household size (AOR
0.73; 95%CI 0.66–0.81); highest household income quartile (AOR
0.27; 95%CI 0.07–1.12). There was no significant association
between catastrophic health expenditures and household having a
health insurance scheme (AOR 0.59; 95%CI 0.13–2.55).
Differences between patients who were excluded due to missing
CD4 counts and patients who were included in the study were
significant for mean age (34 vs. 37 years, p,0.01) and mean health
expenditures among HIV-uninfected members of households ($5.8
vs. $10.4/month, p=0.01). Differences in all other variables,
including total household expenditures, total health expenditures
and food expenditures, were not significant.
Discussion
We investigated the burden of health care expenditures among
households with HIV-infected adults on ART in Co ˆte d’Ivoire,
West Africa. Our findings add to the literature on the economic
impact of chronic diseases such as HIV/AIDS on households in
resource-limited settings [6,12–20].
In the early era of large HIV care and treatment programmes in
sub-Saharan Africa, the emphasis has been on improving access to
Table 1. Characteristics of patients and households (N=1190).
Patient characteristics
Most recent CD4 count (cell/mm
3), median (IQR) 187 (88–301)
Median time (months) since most recent CD4 count, median (IQR) 5.5 (3.4–7.5)
CD4 stratum (cell/mm
3), number (%)
,100 330 (27.7)
100–199 301 (25.3)
200–349 332 (27.9)
350–499 124 (10.4)
$500 104 (8.7)
Time spent on ART (months), median (IQR) 14 (7–23)
Age (years), median (IQR) 37 (31–43)
Women, number (%) 857 (72)
Employment sector of the patient, number (%)
Formal 167 (14)
Informal 559 (47)
Unemployed 464 (39)
Patient is household head, number (%) 535 (45)
Structure of the households
Number of household members, median (IQR) 5 (3–8)
Level of education of the household head, number (%)
None 500 (42)
Primary 286 (24)
Secondary 309 (26)
University 95 (8)
Footnotes for table 1:
%: percentage.
IQR: interquartile range.
ART: antiretroviral therapy.
Most recent CD4 count: all within the past 12 months; median time since the
most recent CD4 count was 5.5 months (IQR 3.4; 7.5).
Formal sector: public or private sector employment registered with the income
(or profit) tax authorities.
Informal sector: employment in at least one unorganized enterprise in the last 7
days, irrespective of employment status and regardless of whether it was the
primary or secondary job.
doi:10.1371/journal.pone.0011213.t001
Table 2. Household expenditures.
Mean value US$ per month (SD) Mean percentage
Total household expenditures* 313.8 (14.9) 100%
Food expenditures 100.1 (2.2) 39.7%
Non-food non-health expenditures 189.4 (14.2) 50.5%
Health expenditures 24.3 (1.5) 9.9% 100%
For the HIV-infected study subject 13.8 (0.7) - 75.3% 100%
Antiretroviral drugs and CD4 count tests 1.9 (0.0) - - 24.6%
Other medical costs** 8.8 (0.7) - - 50.1%
Transportation 3.1 (0.2) - - 25.3%
Other members of the household 10.5 (1.2) - 24.7% -
Footnotes for table 2:
ARV: antiretroviral.
Capacity-to-pay: non-subsistence expenses, i.e. total household expenditures minus food expenditures.
*Self-declared expenditures in FCFA converted at exchange rate US$1=420 FCFA at time of survey (June–July 2007).
**Other drugs and tests, medical consultations, and hospital stays.
doi:10.1371/journal.pone.0011213.t002
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out-of-pocket payments for drugs and tests act as a barrier to care,
and that clinical outcomes are worse in settings in which drugs and
routine tests are not free [4,21,22,23,24]. These findings have
largely contributed to the decision of program funders to make
ARV drugs and routine tests available free of charge throughout
the continent.
ARV drugs and routine tests were available at a very low cost in
Co ˆte d’Ivoire at the time of our study, and have recently become
entirely free. Our study suggests that this decision is unlikely to
alleviate the economic burden of HIV care on households, because
the majority of health expenditures are for non-ARV drugs, non-
routine tests, medical consultations and hospital stays. A significant
proportion of households with patients on ART, therefore,
continue to be confronted with catastrophic health expenditures.
Catastrophic health expenditures are defined as health care costs
that constitute a large share of household resources and either
divert from consumption of basic goods or force the household to
use savings, sell assets, or borrow money [10,25]. Our results
strongly suggest that morbidity events in patients on ART
represent a significant economic burden for households, even
when patients have CD4 counts above 200 [26]. In multivariate
analysis, the risk of catastrophic household health expenditures
decreased with increased time spent on ART, female HIV-infected
patients, head of household education level and household size. As
expected, households with higher incomes were at lower risk of
incurring catastrophic health expenditures than households with
lower incomes [14,27]. Several hypotheses may explain our
finding that the households of HIV-infected women are less likely
to be associated with catastrophic spending. First, female patients
may have unequal access to care compared to men. Their health
expenditures may therefore be lower than those of male patients.
Our finding is more likely due, however, to the fact that women in
Co ˆte d’Ivoire are generally not the main income earner of their
household. HIV-infected women thus have a smaller impact on
their households than HIV-infected men. When the HIV-infected
person is the main income earner, time since infection becomes a
critical factor in determining whether household expenditures will
become catastrophic. If the patient’s disease worsens, health
expenditures increase and other household expenditures become
more difficult to sustain. We also found that the presence or
absence of health insurance had no impact on results, suggesting
that having insurance does not protect households from cata-
strophic spending.
Our study has several limitations. First, we only calculated
direct costs. If we had integrated indirect costs, such as time and
opportunity costs, we likely would have found that morbidity
events in patients on ART with low or intermediate CD4 counts
leads to losses in income and productivity [12,17,28]. Income
losses reduce household capacity-to-pay, while productivity losses
result in a burden for the community. We probably took some
income losses into account when we estimated overall household
expenses and capacity-to-pay, but our survey did not deal with
productivity losses. Therefore, we cannot determine the impact of
non-ART and non-routine HIV care on the community.
Second, we estimated the household burden of health
expenditures by estimating the proportion of the capacity-to–pay
Figure 1. Household health expenditures for HIV-infected
patients and other members of the family by CD4 count.
Footnotes for figure 1:N Expenditures for the HIV-infected patient
by CD4 count, overall p value,0.001. N Expenditures for other
household members by CD4 count, overall p value=0.77. N Overall
health expenditures by CD4 count, overall p value=0.03.
doi:10.1371/journal.pone.0011213.g001
Figure 2. Categories of health expenditures for HIV-infected
patients by CD4 count. Footnotes for figure 2:N ARV drugs and
routine tests by CD4 count, overall p value,0.001. N Other medical
costs (non ARV drugs, non-routine tests, consultations, hospital stays)
by CD4 count, overall p value=0.0001. N Non-medical costs
(transportation) by CD4 count, overall p value=0.14.
doi:10.1371/journal.pone.0011213.g002
Figure 3. Health expenditures/capacity-to-pay ratio.
doi:10.1371/journal.pone.0011213.g003
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overall household expenditures, not household self-declared
income. We used this method, because the sum of self-reported
expenditures is considered to be a better approximation of the
household’s real purchasing power than the sum of self-reported
incomes [9]. However, this method does not consider health
expenditures that may have been reimbursed by insurance
companies. We may have overestimated the burden of health
expenditures among the 9% of households who declared having
health insurance [8]. However, households with health insurance
are generally wealthier than those without it [29], so it is unlikely
that they introduced a major bias in our main results.
This study likely underestimated the economic consequences of
HIV care on households, for several reasons. First, we were only
able to gather data on one HIV-infected patient per household. In
households with more than one HIV-patient, total household
health expenditures were probably significantly higher. Second,
we excluded 6.7% of patients from the study because they had not
performed CD4 count tests. Although total household expendi-
tures and total health expenditures did not differ significantly
between excluded patients and included patients, it is still possible
that excluded patients were poorer than patients who were
included in the study. Third, some authors suggest using shorter
recall periods for regular purchases like food, and longer recall
periods for durable goods such as rent [15]. Because we asked
households to recall all expenditures, including food and housing,
in the previous 3 months, we may have underestimated both
regular purchases and durable goods. Fourth, 16 of the 18 study
centers were in the economic capital of Co ˆte d’Ivoire and probably
provide care to the wealthier segments of the country’s population.
Catastrophic health expenditures are likely to be even higher in
other regions of Co ˆte d’Ivoire. Finally, some households may have
been using outside funds to cope with the health expenditures
associated with HIV at the time of the survey, as suggested by
previous studies [12,18,30]. The use of precautionary savings,
depletion of assets, and money borrowed from friends and relatives
to pay for both health care and other expenses (e.g. school) may
have inflated the capacity-to-pay and reduced the perceived
proportion of households with catastrophic health expenditures
[12,13,15,30–33].
To our knowledge, no other study in Co ˆte d’Ivoire has
estimated the expenditures of households with at least one HIV-
infected member. We therefore cannot compare our results to
previous studies. Nor can we declare that our sample is
representative, because our survey was not conducted at the
national level. That said, a 2008 national survey of the standard of
living in households across Co ˆte d’Ivoire (National Household
Living Standard Survey) found that 47.8% of household expenses
were related to food, 5.8% were related to health care and 3.7%
were related to education [34]. In our study, the proportion of
total household expenditures devoted to food (39.7%) was lower
than in the general population, while the proportion of total
household expenditures used for health-related needs (9.9%) was
much higher than in the general population.
Finally, the time since HIV diagnosis at the time of the survey
was unknown. It is likely that as households continue to cope with
HIV-related health expenses over time, the financial burden
becomes increasingly large.
We used a 40% health expenditures/capacity-to-pay ratio to
define catastrophic health expenditures, consistent with the WHO
definition [10,14,25]. Other studies have used thresholds of 5% or
20% to define health expenditures as high burdens for the
household [12,27,35]. When we varied the threshold from 20% to
60%, the percentage of households facing catastrophic health
expenditures was 10–28%. While the 40% ratio is commonly used,
there is no definitive threshold for establishing when expenditures
become catastrophic [14]. This approximate threshold represents
the limit under which households must sacrifice basic needs, sell
productive assets, incur debt, or be impoverished, in order to
finance health expenditures [12,30,36].
In conclusion, our findings suggest that innovative schemes
should be developed to help HIV-infected patients on ART face
the cost of morbidity events. The recent decision by the
Table 3. Factors associated with catastrophic health
expenditures (threshold/cut-off level=40%) among
household with HIV-infected patients.
AOR (95%CI) P-value
Patient characteristics
CD4 (cells/mm
3)
#200 0.87 (0.45–1.67) 0.68
[200–350] 1.04 (0.51–2.11) 0.91
$350 1
Time spent on ART 0.97 (0.94–0.99) 0.00
Age (years) 1.02 (0.99–1.05) 0.19
Patient is household head
Yes 1
No 0.79 (0.46–1.35) 0.38
Female
Yes 1
No 0.58 (0.46–1.33) 0.04
Employment sector of the patient
Formal 1
Informal 1.80 (0.69–4.66) 0.23
Unemployed 1.90 (0.41–8.79) 0.41
Household characteristics
Income quartiles
Lowest quartile 1
Lower middle quartile 2.45 (0.65–9.17) 0.18
Upper middle quartile 1.13 (0.33–3.85) 0.85
Highest quartile 0.27 (0.07–1.12) 0.07
Household size 0.73 (0.66–0.81) 0.00
Insurance status
Yes 1
No 0.59 (0.13–2.55) 0.48
Level of education of the household head
No education 1
Primary 0.88 (0.53–1.44) 0.61
Secondary 0.31 (0.15–0.63) 0.00
University - -
Footnotes for table 3:
AOR: Adjusted Odds Ratio; CI: Confidence Interval.
ART: antiretroviral therapy.
Most recent CD4 count: all within the past 12 months; median time since the
most recent CD4 count was 5.5 months (IQR 3.4; 7.5).
Formal sector: public or private sector employment registered with the income
(or profit) tax authorities.
Informal sector: employment in at least one unorganized enterprise in the last 7
days, irrespective of employment status and regardless of whether it was the
primary or secondary job.
doi:10.1371/journal.pone.0011213.t003
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for free should be considered as a first step, but additional steps
must be taken to further alleviate the burden of HIV/AIDS care
and treatment in patients on ART [37–40].
Abolishing user fees would mean higher real costs for funders
[41,42]. Financing strategies, such as pre-payments and commu-
nity-based or micro-insurance risk pooling, could be implemented
to make households participate in reducing costs, while simulta-
neously preventing catastrophic financial situations. The aim of a
new financing system should be to improve access to care,
especially for concurrent morbidity events, to protect people from
catastrophic financial expenses and subsequent impoverishment,
and to offer equitable and efficient health benefits [43–48]. One
attractive operational scheme might be a National HIV/AIDS
Care Equity Fund, which could be financed by international
donors, national authorities and households. This type of system,
however, should not be designed in isolation, but in combination
with strategies, including a national social security system and
public-private partnerships [49–51]. Further studies should assess
the feasibility, sustainability and operational challenges of a
National HIV/AIDS Care Equity Fund.
Acknowledgments
We are grateful to thepatients whoparticipated in the study, members of the
National Program on HIV-care (PNPEC) team (Abidjan, Co ˆte d’Ivoire),
members of the Programme PAC-CI team (Abidjan, Co ˆte d’Ivoire),
members of the Association Aconda team (Abidjan, Co ˆte d’Ivoire) and
members of the Cost-effectiveness of Preventing AIDS Complications
(CEPAC) team (Boston, USA).
Author Contributions
Conceived and designed the experiments: AB ST KK BK FD SE XA.
Analyzed the data: AB PKA AP NJ JS. Contributed reagents/materials/
analysis tools: AB ST PKA AP KK BK NJ JS VET FD SE XA. Wrote the
paper: AB ST PKA AP KK BK NJ JS VET FD SE XA. Responsible for
the study coordination: AB. Co-responsible for the study coordination: ST.
References
1. WHO (2008) The World Health Report 2008. Primary health care. Now more
than ever. Geneva: WHO. Available:http://www.who.int/whr/2008/
whr08_en.pdf. Accessed 19 February 2009.
2. WHO, UNAIDS, Unicef (2009) Toward universal access. Scaling up priority
HIV/AIDS interventions in the health sector. Progress report 2009. Geneva:
WHO. Available:http://www.who.int/hiv/pub/tuapr_2009_en.pdf. Accessed
5 October 2009.
3. Ministe `re de la Lutte contre le Sida (2008) Suivi de la de ´claration d’engagement
sur le VIH/SIDA (UNGASS). Rapport national de la Co ˆte d’Ivoire 2008.
Abidjan: Ministe `re de la Lutte contre le Sida. Available:http://data.unaids.org/
pub/Report/2008/cote_divoire_2008_country_progress_report_fr.pdf. Ac-
cessed 28 July 2008.
4. Brinkhof MW, Boulle A, Weigel R, Messou E, Mathers C, et al. (2009) Mortality
of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa:
comparison with HIV-unrelated mortality. PLoS Med 6: e1000066.
5. Boyer S, Marcellin F, Ongolo-Zogo P, Abega SC, Nantchouang R, et al. (2009)
Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a
national cross-sectional survey. Bull World Health Organ 87: 279–287.
6. Onwujekwe O, Dike N, Chukwuka C, Uzochukwu B, Onyedum C, et al. (2009)
Examining catastrophic costs and benefit incidence of subsidized antiretroviral
treatment (ART) programme in south-east Nigeria. Health Policy 90: 223–229.
7. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, et al. (2008)
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d’Ivoire:
2-year outcomes and determinants. AIDS 22: 873–882.
8. Murray CJ, Evans DB, eds. (2003) Health systems performance assessment:
debates, methods and empiricism. Geneva: World Health Organization. 900 p.
9. Deaton A, ed. (1997) The analysis of household surveys: a microeconometric
approach to development policy. Baltimore: The Johns Hopkins University
Press. 488 p.
10. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, et al. (2003) Household
catastrophic health expenditure: a multicountry analysis. Lancet 362: 111–117.
11. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM (2005) Designing health
financing systems to reduce catastrophic health expenditure. Technical briefs for
policy-makers no 2. Geneva: World Health Organization, Available: http://
www.who.int/health_financing/pb_2.pdf. Accessed 11 May 2009.
12. Russell S (2004) The economic burden of illness for households in developing
countries: a review of studies focusing on malaria, tuberculosis, and human
immunodeficiency virus/acquired immunodeficiency syndrome. Am J Trop
Med Hyg 71: 147–155.
13. Wagstaff A, van Doorslaer E (2003) Catastrophe and impoverishment in paying
for health care: with applications to Vietnam 1993–1998. Health Econ 12:
921–934.
14. van Doorslaer E, O’Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR,
et al. (2007) Catastrophic payments for health care in Asia. Health Econ 16:
1159–1184.
15. Somkotra T, Lagrada LP (2009) Which households are at risk of catastrophic
health spending: experience in Thailand after universal coverage. Health Aff
(Millwood) 28: w467–478.
16. Wyszewianski L (1986) Families with catastrophic health care expenditures.
Health Serv Res 21: 617–634.
17. Veenstra N, Whiteside A (2005) Economic impact of HIV. Best Pract Res Clin
Obstet Gynaecol 19: 197–210.
18. McIntyre D, Thiede M, Dahlgren G, Whitehead M (2006) What are the
economic consequences for households of illness and of paying for health care in
low- and middle-income country contexts? Soc Sci Med 62: 858–865.
19. Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, et al. (2008) Costing
universal access of highly active antiretroviral therapy in Benin. AIDS Care 20:
582–587.
20. Taverne B, Diop K, Vinard P (2008) The cost of universal free access for treating
HIV/AIDS in low-income countries: the case of Senegal. In: Coriat B, ed. The
political Economy of HIV/AIDS in Developing Countries TRIPS, Public
Health Systems and Free Access. London: Edward Elgar. pp 273–290.
21. Msellati P, Juillet-Amari A, Prudhomme J, Akribi HA, Coulibaly-Traore D,
et al. (2003) Socio-economic and health characteristics of HIV-infected patients
seeking care in relation to access to the Drug Access Initiative and to
antiretroviral treatment in Cote d’Ivoire. AIDS 17 Suppl 3: S63–68.
22. Katzenstein D, Laga M, Moatti JP (2003) The evaluation of the HIV/AIDS
drug access initiatives in Cote d’Ivoire, Senegal and Uganda: how access to
antiretroviral treatment can become feasible in Africa. AIDS 17 Suppl 3: S1–4.
23. Furber AS, Hodgson IJ, Desclaux A, Mukasa DS (2004) Barriers to better care
for people with AIDS in developing countries. BMJ 329: 1281–1283.
24. Posse M, Meheus F, van Asten H, van der Ven A, Baltussen R (2008) Barriers to
access to antiretroviral treatment in developing countries: a review. Trop Med
Int Health 13: 904–913.
25. Xu K, Evans DB, Kadama P, Nabyonga J, Ogwal PO, et al. (2006)
Understanding the impact of eliminating user fees: utilization and catastrophic
health expenditures in Uganda. Soc Sci Med 62: 866–876.
26. Nombela N, Kouadio B, Toure S, Seyler C, Flori YA, et al. (2006)
Nonantiretroviral drug consumption by CD4 cell count in HIV-infected adults:
a 5-year cohort study in Cote d’Ivoire. J Acquir Immune Defic Syndr 41:
225–231.
27. Su TT, Kouyate B, Flessa S (2006) Catastrophic household expenditure for
health care in a low-income society: a study from Nouna District, Burkina Faso.
Bull World Health Organ 84: 21–27.
28. Duraisamy P, Ganesh AK, Homan R, Kumarasamy N, Castle C, et al. (2006)
Costs and financial burden of care and support services to PLHA and
households in South India. AIDS Care 18: 121–127.
29. WHO (2009) World Health Statistics. Geneva: World Health Organization.
149 p.
30. Russell S (1996) Ability to pay for health care: concepts and evidence. Health
Policy Plan 11: 219–237.
31. Pradhan M, Prescott N (2002) Social risk management options for medical care
in Indonesia. Health Econ 11: 431–446.
32. Van Damme W, Meessen B, Por I, Kober K (2003) Catastrophic health
expenditure. Lancet 362: 996; author reply 997.
33. Flores G, Krishnakumar J, O’Donnell O, van Doorslaer E (2008) Coping with
health-care costs: implications for the measurement of catastrophic expenditures
and poverty. Health Econ 17: 1393–1412.
34. International Monetary Fund (IMF) (2009) Co ˆte d’Ivoire: Poverty Reduction
Strategy Paper. Washington: International Monetary Fund. Available: http://
planipolis.iiep.unesco.org/upload/Cote%20Ivoire/Cote_dIvoire_prsp_2009.
pdf. Accessed 20 May 2010.
35. Lu C, Chin B, Li G, Murray CJ (2009) Limitations of methods for measuring
out-of-pocket and catastrophic private health expenditures. Bull World Health
Organ 87: 238–244.
36. Russel S, Gilson L (2006) Are health services protecting the livelihoods the urban
poor in Sri Lanka? Findings from two low-income areas of Colombo. Soc Sci
Med 63: 1732–1744.
37. Souteyrand YP, Collard V, Moatti JP, Grubb I, Guerma T (2008) Free care at
the point of service delivery: a key component for reaching universal access to
HIV/AIDS treatment in developing countries. AIDS 22 Suppl 1: S161–168.
Financial Burden of HIV/AIDS
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e1121338. Zachariah R, Van Engelgem I, Massaquoi M, Kocholla L, Manzi M, et al.
(2008) Payment for antiretroviral drugs is associated with a higher rate of
patients lost to follow-up than those offered free-of-charge therapy in Nairobi,
Kenya. Trans R Soc Trop Med Hyg 102: 288–293.
39. Mukherjee JS, Ivers L, Leandre F, Farmer P, Behforouz H (2006) Antiretroviral
therapy in resource-poor settings. Decreasing barriers to access and promoting
adherence. J Acquir Immune Defic Syndr 43 Suppl 1: S123–126.
40. Vinard P, Diop K, Taverne B (2008) Implementing funding modalities for free
access: The case for a ‘‘purchasing fund system’’ to cover medical care. In:
Coriat B, ed. The political Economy of HIV/AIDS in Developing Countries
TRIPS, Public Health Systems and Free Access. London: Edward Elgar. pp
291–311.
41. Palmer N, Mueller DH, Gilson L, Mills A, Haines A (2004) Health financing to
promote access in low income settings-how much do we know? Lancet 364:
1365–1370.
42. James CD, Hanson K, McPake B, Balabanova D, Gwatkin D, et al. (2006) To
retain or remove user fees?: reflections on the current debate in low- and middle-
income countries. Appl Health Econ Health Policy 5: 137–153.
43. Gilson L, Kalyalya D, Kuchler F, Lake S, Oranga H, et al. (2001) Strategies for
promoting equity: experience with community financing in three African
countries. Health Policy 58: 37–67.
44. Ranson MK (2002) Reduction of catastrophic health care expenditures by a
community-based health insurance scheme in Gujarat, India: current experi-
ences and challenges. Bull World Health Organ 80: 613–621.
45. Bennett S (2004) The role of community-based health insurance within the
health care financing system: a framework for analysis. Health Policy Plan 19:
147–158.
46. Carrin G, Waelkens MP, Criel B (2005) Community-based health insurance in
developing countries: a study of its contribution to the performance of health
financing systems. Trop Med Int Health 10: 799–811.
47. Molyneux C, Hutchison B, Chuma J, Gilson L (2007) The role of community-
based organizations in household ability to pay for health care in Kilifi District,
Kenya. Health Policy Plan 22: 381–392.
48. Leive A, Xu K (2008) Coping with out-of-pocket health payments: empirical
evidence from 15 African countries. Bull World Health Organ 86: 849–856.
49. Carrin G, Mathauer I, Xu K, Evans DB (2008) Universal coverage of health
services: tailoring its implementation. Bull World Health Organ 86: 857–863.
50. Lange JM, Schellekens OP, Lindner M, van der Gaag J (2008) Public-private
partnerships and new models of healthcare access. Curr Opin HIV AIDS 3:
509–513.
51. Samb B, Evans T, Dybul M, Atun R, Moatti JP, et al. (2009) An assessment of
interactions between global health initiatives and country health systems. Lancet
373: 2137–2169.
Financial Burden of HIV/AIDS
PLoS ONE | www.plosone.org 7 June 2010 | Volume 5 | Issue 6 | e11213